HC Wainwright & Co. Reiterates Buy on eFFECTOR Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on eFFECTOR Therapeutics (NASDAQ:EFTR) and maintained a $5 price target for the company's stock.

November 14, 2023 | 11:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reaffirmed a Buy rating on eFFECTOR Therapeutics and kept the price target at $5, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst like Robert Burns could lead to increased investor confidence and a potential short-term uplift in EFTR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100